<a href="https://laohu8.com/S/EDIT">Editas Medicine</a>'s CD19 HD Allo CAR T Program Receives IND/CTA Acceptance, Secures Milestone Payment Through Collaboration with Bristol Myers Squibb
Editas Medicine Inc., a pioneering gene editing company, has announced a significant milestone in its collaboration with Bristol Myers Squibb. The company has successfully secured its first IND/CTA acceptance for the CD19 HD Allo CAR T program, marking a crucial step forward in their joint efforts. This acceptance has also triggered a milestone payment to Editas, highlighting the progress and potential of their collaborative program. This development is part of Editas' broader strategy to advance transformative medicines for serious diseases and underscores their ongoing commitment to innovation in gene editing.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001650664-25-000123), on August 12, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。